Medindia
Why Register as Premium Member if you have Diabetes? Click Here
Medindia » Health In Focus

Skin Cancer Treatment may Benefit Wound Healing

by Dr. Simi Paknikar on August 3, 2016 at 5:36 PM
Listen to this News

Highlights


A group of medications called BRAF inhibitors used in the treatment of a particular type of skin cancer may promote wound healing, according to a study conducted by researchers from the University of California and published in Nature Communications.

‘Increased skin proliferation due to a side effect of BRAF inhibitors is a potential treatment for chronic wounds.’

Chronic wounds due to injury or other causes interfere with the barrier function of the skin. They are difficult to treat and often require skin grafting. Application of a local medicine to promote the skin healing process would definitely make treatment simpler and less expensive. Researchers evaluated the topical use of an anticancer drug belonging to the group BRAF inhibitors called vemurafenib to aid the healing of skin wounds.

BRAF is a human gene which is capable of making a protein called B-Raf.The cancer-fighting BRAF inhibitors are drugs used for the treatment of a particular type of melanoma, a potentially lethal skin cancer that arises from the pigment cells of the skin. These drugs block a mutated gene in the cancer cells, thereby causing the tumor to shrink.

One of the main side effects of BRAF inhibitors is an excessive growth of skin. This occurs due to the activation of the mitogen-activated protein kinase (MAPK) pathway at the cellular level. This skin-related side effect of these drugs is being explored as a therapeutic potential - to help the skin to re-grow and aid in wound healing.

Researchers tested the wound healing benefits of vemurafenib in cell cultures as well as in animal studies. They found that:

The enhanced proliferation of skin cells was inhibited by trametinib - mitogen activated protein kinase enzyme inhibitor (MEK inhibitor), which blocks the MAPK activation. This confirms that the mitogen-activated protein kinase (MAPK) pathway is indeed responsible for the skin growth and thickening caused by vemurafenib.

The use of topical BRAF inhibitors is a promising prospect for the treatment of wounds. However, they are still in the testing process and there is still a long time before these drugs can be made available for use in humans for this purpose.

References:

  1. Escuin-Ordinas H et al. Cutaneous Wound Healing Through Paradoxical MAPK Activation by BRAF Inhibitors. Nature Communications 7, Article number: 12348 doi:10.1038/ncomms12348
Source: Medindia

Cite this Article

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dr. Simi Paknikar. (2016, August 03). Skin Cancer Treatment may Benefit Wound Healing. Medindia. Retrieved on Dec 16, 2024 from https://www.medindia.net/news/healthinfocus/skin-cancer-treatment-may-benefit-wound-healing-162310-1.htm.

  • MLA

    Dr. Simi Paknikar. "Skin Cancer Treatment may Benefit Wound Healing". Medindia. Dec 16, 2024. <https://www.medindia.net/news/healthinfocus/skin-cancer-treatment-may-benefit-wound-healing-162310-1.htm>.

  • Chicago

    Dr. Simi Paknikar. "Skin Cancer Treatment may Benefit Wound Healing". Medindia. https://www.medindia.net/news/healthinfocus/skin-cancer-treatment-may-benefit-wound-healing-162310-1.htm. (accessed Dec 16, 2024).

  • Harvard

    Dr. Simi Paknikar. 2016. Skin Cancer Treatment may Benefit Wound Healing. Medindia, viewed Dec 16, 2024, https://www.medindia.net/news/healthinfocus/skin-cancer-treatment-may-benefit-wound-healing-162310-1.htm.

View Non AMP Site | Back to top ↑